Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 5/20 | 0.40 |
| ▸ | FPR1 | P21462 | 4/20 | 0.38 |
| ▸ | FPR2 | P25090 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 4/20 | 0.33 |
| ▸ | HTR2B | P41595 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160785 | 0.89 | SLC6A2 (0.37) | RENSLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL5158640 | 0.89 | SLC6A4 (0.40) | RENFPR1FPR2SLC6A4SLC6A2 | |
| SCHEMBL5159568 | 0.82 | HTR2C (0.38) | RENSLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL5156682 | 0.82 | HTR6 (0.38) | SLC6A4SLC6A2SLC6A3KCNH2HTR1A | |
| SCHEMBL5158072 | 0.81 | HTR2A (0.41) | SLC6A4SLC6A2SLC6A3KCNH2HTR1A | |
| SCHEMBL5158982 | 0.81 | HTR6 (0.40) | RENSLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL5161524 | 0.80 | SLC6A2 (0.41) | RENSLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL5156155 | 0.80 | SLC6A2 (0.44) | RENSLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL5158889 | 0.80 | SLC6A2 (0.43) | RENSLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL5161560 | 0.79 | SLC6A2 (0.47) | RENSLC6A4SLC6A2SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | REN 610/4885FPR1 607/4885FPR2 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.